Pentoxifylline's effect on cognitive impairment after ischemic stroke
Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke and Its Mechanism of Brain Electricity and Brain Metabolism
This study is testing if the drug pentoxifylline can help improve thinking and memory problems in people who have had an ischemic stroke.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | The First Hospital of Hebei Medical University Academic / other |
| Locations | 1 site (Shijiazhuang) |
| Trial ID | NCT06344390 on ClinicalTrials.gov |
What this trial studies
This study investigates the potential of pentoxifylline to improve cognitive impairment in patients who have experienced an ischemic stroke. Participants will be randomly assigned to receive either pentoxifylline or a placebo, alongside standard treatments for ischemic stroke. The study will utilize advanced imaging techniques, such as transcranial Doppler and functional MRI, to assess changes in cerebral blood flow and neuronal activity. The goal is to understand the biological mechanisms behind cognitive improvements following treatment.
Who should consider this trial
Good fit: Ideal candidates are Han Chinese individuals aged 40-80 with cognitive impairment following an ischemic stroke and a specific NIHSS score.
Not a fit: Patients with pre-existing dementia or severe mental illness, or those unable to undergo necessary examinations, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly enhance cognitive recovery in stroke patients, improving their quality of life.
How similar studies have performed: While pentoxifylline has been studied for various conditions, its specific application for cognitive impairment post-stroke is less explored, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Han Chinese, age 40-80 years old, male and female, right-handed; * The diagnosis is consistent with the Expert Consensus on the Management of Cognitive Impairment after Stroke 2021; * NIHSS score 1-15 points; * Daily Living Ability Scale (ADL) ≥75 score; * The Informed consent signed by the patient or his legal representative Exclusion Criteria: * Can not cooperate with the examination (including neuropsychological tests and scale assessment); * There were memory disorders, dementia with lewy bodies and frontotemporal dementia before the onset of stroke events; * There were definite infectious diseases 2 weeks before admission; Have a serious mental illness, previous history of cancer, alcohol or drug abuse; * Use of drugs that may affect cognitive function, including sedatives, anti-anxiety drugs, hypnotics, nootropic drugs, and cholinoid drugs; * Can not accept brain MRI examination
Where this trial is running
Shijiazhuang
- BHan — Shijiazhuang, China (Recruiting)
Study contacts
- Principal investigator: Jiaying Rong, master — The First Hospital of Hebei Medical University
- Study coordinator: Bing Han, Ph.D. degree
- Email: Hanbing1987@hebmu.edu.cn
- Phone: 13784333398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.